Andrzej P. KudelkaApichai VasuratnaCreigton L. EdwardsKristan AugustineMongkol BenjapibalClaire F. VerschraegenJohn J. KavanaghUniversity of Texas MD Anderson Cancer CenterChulalongkorn UniversityMahidol University2018-07-042018-07-041998-01-01Anti-Cancer Drugs. Vol.9, No.7 (1998), 621-623095949732-s2.0-0031656655https://repository.li.mahidol.ac.th/handle/20.500.14594/18330A 19-year-old woman with refractory juvenile granulosa cell tumors had persistent disease after PVB (cisplatin, vinblastino and bleomycin) and multiple high doses of ICE (ifosfamide, carboplatin and etoposide) with peripheral stem cell support. She achieved stable disease for 4 months with low dose intensity gemcitabine of 500 mg/m2/week. The planned dose had been 1250 mg/m2/week. The dose intensity was limited by myelosuppression especially thrombocytopenia. The use of thrombopoietic, in addition to erythropoietic and myelopoletic, agents may permit higher dose intensity of gemcitabine after bone marrow ablative therapy with resulting greater anti tumor activity.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyMedicinePharmacology, Toxicology and PharmaceuticsArticleSCOPUS10.1097/00001813-199808000-00007